This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Symphony Capital LLC
Drug Names(s): NIL-A
Description: GPI 1485 belongs to a class of compounds called neuroimmunophilin ligands. Neuroimmunophilin ligands are small molecules that in preclinical experiments have been shown to be orally bioavailable, cross the blood-brain barrier, and repair and regenerate damaged nerve terminals without affecting normal nerves.
Deal Structure: In August 1997, Guilford entered into a collaboration with Amgen to develop and commercialize a broad class of NILs for all human therapeutic and diagnostic applications. During 1998, Amgen nominated GPI 1485, which was then named NIL-A, to serve as a lead compound for the program and initially targeting Parkinsons disease. In September 2001, Amgen terminated the collaboration and, thereafter, returned all rights in the NIL technology to Guilford.
In June 2004, Guilford Pharmaceuticals licensed to Symphony Neuro Development Company, a newly formed Delaware corporation (SNDC), its rights to GPI 1485 for certain indications in the United States. SNDC will invest up to $40 million to advance GPI 1485 through clinical development.
On October 3, 2005, MGI PHARMA closed its previously-announced acquisition of Guilford Pharmaceuticals Inc.
In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the...See full deal structure in Biomedtracker
Partners: Eisai Co., Ltd.
GPI 1485 News
Pink Sheet Guilford restructuring
Pink Sheet Ex-Bristol Exec Named Guilford CFO
Additional information available to subscribers only: